Funding Opportunities

PDBP Funding opportunities (FOAs) support discovery projects designed to promote the identification of promising diagnostic and progression biomarkers for Parkinson's disease.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

Annoucement Type:
Reissue of PAR-18-550 - Analytical Validation of a Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional)
Application Due Date:
Activity Code:
U01 Research Project – Cooperative Agreements
Letter of Intent Due Date:
FOA Number:
PAR-21-056
Contact:
Mary Ann Pelleymounter & Carol Taylor-Burds

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

Annoucement Type:
Reissue of PAR-18-664
Application Due Date:
Activity Code:
U01 Research Project – Cooperative Agreements
Letter of Intent Due Date:
FOA Number:
PAR-21-058
Contact:
Mary Ann Pelleymounter & Carol Taylor-Burds

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Treatments for Lewy Body Dementias--Exploratory Clinical Trial (U01 Clinical Trial Required)

Annoucement Type:
New
Application Due Date:
Activity Code:
U01 Research Project – Cooperative Agreements
Letter of Intent Due Date:
FOA Number:
RFA-NS-21-008
Contact:
Debra Babcock, PhD, MD

Funding Opportunity Purpose

This Funding Opportunity Announcement invites applications from investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD). Applicants may propose to conduct either Phase I or Phase II clinical trials depending on the developmental stage of the potential therapeutic, but all trials must include patients with LBD. Proposed therapies may include novel medications or devices, or existing treatments that are potentially beneficial but not currently approved for use in patients with LBD. Treatments intended to prevent or delay disease progression in LBD patients, as well as therapies to alleviate existing motor or non-motor clinical symptoms, are of interest.

NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)

Annoucement Type:
Reissue of PAR-17-102
Application Due Date:
Activity Code:
U01
FOA Number:
PAR-18-422
Contact:
Peter Gilbert, ScM

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions.  These Phase 3, Phase 4 or Pivotal trials must address questions within the mission and research interests of the NINDS and may include studies of drugs, biologics, and devices, as well as surgical, behavioral or rehabilitation therapies.

Dissemination and Implementation Research in Health (R01, R21, R03)

Annoucement Type:
Reissue of PAR-18-007
Activity Code:
R01, R21, R03
FOA Number:
PAR-19-274
Contact:
Peter Gilbert, Sc.M.

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

Companion Funding Opportunity:

PAR-19-275, R21 Exploratory/Developmental Grant

PAR-19-276, R03 Small Grant Program  

Contact: Peter.Gilbert@nih.gov